Given that the alpelisib-fulvestrant combination is a clinical standard for ER+/HER2- breast cancer[50], our results suggest that patients with high FGFR1 expression might benefit from this modified regimen, thereby enhancing clinical outcomes in resistant cases. The gene discussed is ERBB2; the disease is breast carcinoma.